• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Clinical Laserthermia Systems

3.48 SEK

+1.16 %

Less than 1K followers

CLS B

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.16 %
-27.95 %
-36.73 %
-49.42 %
-51.05 %
+25.41 %
-85.78 %
-97.82 %
-98.59 %

Clinical Laserthermia Systems operates in the medical technology sector. The company's vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as in the treatment of malignant melanoma, as well as cancer of the lungs, liver and pancreas. The company was founded in 2006 and has its headquarters in Lund.

Read more
Market cap
108.46M SEK
Turnover
53.96K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.6.
2026

General meeting '26

29.8.
2026

Interim report Q2'26

13.11.
2026

Interim report Q3'26

Regulatory press release6/4/2026, 6:30 AM

CLS: Clinical Laserthermia Systems publishes annual report for 2025

Clinical Laserthermia Systems
Regulatory press release5/28/2026, 1:00 PM

CLS enters research agreement with the U.S. National Cancer Institute

Clinical Laserthermia Systems
Regulatory press release5/28/2026, 6:30 AM

CLS: Notice of Annual General Meeting of Clinical Laserthermia Systems AB June 29, 2026

Clinical Laserthermia Systems

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/13/2026, 9:57 AM

Redeye: CLS (Q1 Review): Well aligned with our expectations

Clinical Laserthermia Systems
Regulatory press release5/12/2026, 6:30 AM

CLS Publishes Interim Report January - March 2026

Clinical Laserthermia Systems
Regulatory press release5/11/2026, 6:30 AM

CLS Receives Largest Purchase Order Worth SEK 23 Million for Prism[®] Business

Clinical Laserthermia Systems
Regulatory press release4/28/2026, 8:45 AM

CLS Strengthens its Strategic Partnership in Neurosurgery and Aims to Become Market Leader in Neuro LITT

Clinical Laserthermia Systems
Press release2/23/2026, 9:14 AM

Redeye: CLS Q4 (Review): Low sales due to alignment discussions with ClearPoint Neuro

Clinical Laserthermia Systems
Regulatory press release2/20/2026, 7:45 AM

CLS: Clinical Laserthermia Systems AB publishes Year-end report January - December 2025

Clinical Laserthermia Systems
Regulatory press release1/8/2026, 7:30 AM

CLS: TRANBERG[®] Thermal Therapy System installed at Andros Clinics for Launch of Ultrasound-Guided Focal Laser Ablation Program in The Netherlands

Clinical Laserthermia Systems
Regulatory press release12/12/2025, 8:00 PM

CLS initiates recruitment process for permanent Chief Financial Officer

Clinical Laserthermia Systems
Regulatory press release12/3/2025, 7:30 AM

CLS: Clinical Laserthermia Systems Submits CE-Marking Application for its ClearPoint Prism[®][ ]branded Neuro Laser Therapy System seeking European Regulatory Approval for use in Neurosurgery

Clinical Laserthermia Systems
Press release11/17/2025, 8:32 AM

Redeye: CLS Q3 (Review) - Soft sales, but better quarters ahead

Clinical Laserthermia Systems
Regulatory press release11/14/2025, 7:30 AM

CLS Publishes Interim Report January - September 2025

Clinical Laserthermia Systems
Regulatory press release10/7/2025, 8:15 PM

CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results

Clinical Laserthermia Systems
Regulatory press release9/30/2025, 11:35 AM

CLS: Clinical Laserthermia Systems AB Raises SEK 20.9 Million Through Full Subscription of Warrants of Series TO 8 B

Clinical Laserthermia Systems
Regulatory press release9/4/2025, 3:00 PM

CLS: Clinical Laserthermia Systems Receives FDA Clearance for Expanded Labeling of the ClearPoint Prism[®] Neuro Laser Therapy System, doubling the addressable U.S market for Neuro LITT

Clinical Laserthermia Systems
Press release8/25/2025, 9:20 AM

Redeye: CLS Q2 - Strong report that reinforces confidence in outlook

Clinical Laserthermia Systems
Regulatory press release8/22/2025, 6:30 AM

CLS publishes half-year report January - June 2025

Clinical Laserthermia Systems
Regulatory press release6/27/2025, 2:35 PM

CLS: Communique from the Annual General Meeting on Friday June 27th in Clinical Laserthermia Systems A

Clinical Laserthermia Systems